Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 206

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Beyond Rapalog Therapy: Preclinical Pharmacology and Antitumor Activity of WYE-125132, an ATP-Competitive and Specific Inhibitor of mTORC1 and mTORC2

Open access
Yu, Ker, Shi, Celine, Toral-Barza, Lourdes, Lucas, Judy, Shor, Boris, Kim, Jae Eun, Zhang, Wei-Guo, Mahoney, Robert, Gaydos, Christine, Tardio, LuAnna, Kim, Sung Kyoo, Conant, Roger, Curran, Kevin, Kaplan, Joshua, Verheijen, Jeroen, Ayral-Kaloustian, Semiramis, Mansour, Tarek S., Abraham, Robert T., Zask, Arie, Gibbons, James J.·2010·Cancer Research

Abstract

The mammalian target of rapamycin (mTOR) is a major component of the phosphoinositide 3-kinase (PI3K)/AKT signaling pathway that is dysregulated in 50% of all human malignancies. Rapamycin and its analogues (rapalogs) partially inhibit mTOR through allosteric binding to mTOR complex 1 (mTORC1) but not mTOR complex 2 (mTORC2), an emerging player in cancer. Here, we report WYE-125132 (WYE-132), a highly potent, ATP-competitive, and specific mTOR kinase inhibitor (IC50: 0.19 ± 0.07 nmol/L; >5,000-fold selective versus PI3Ks). WYE-132 inhibited mTORC1 and mTORC2 in diverse cancer models in vitro and in vivo. Importantly, consistent with genetic ablation of mTORC2, WYE-132 targeted P-AKT(S473) and AKT function without significantly reducing the steady-state level of the PI3K/PDK1 activity biomarker P-AKT(T308), highlighting a prominent and direct regulation of AKT by mTORC2 in cancer cells. Compared with the rapalog temsirolimus/CCI-779, WYE-132 elicited a substantially stronger inhibition of cancer cell growth and survival, protein synthesis, cell size, bioenergetic metabolism, and adaptation to hypoxia. Oral administration of WYE-132 to tumor-bearing mice showed potent single-agent antitumor activity against MDA361 breast, U87MG glioma, A549 and H1975 lung, as well as A498 and 786-O renal tumors. An optimal dose of WYE-132 achieved a substantial regression of MDA361 and A549 large tumors and caused complete regression of A498 large tumors when coadministered with bevacizumab. Our results further validate mTOR as a critical driver for tumor growth, establish WYE-132 as a potent and profound anticancer agent, and provide a strong rationale for clinical development of specific mTOR kinase inhibitors as new cancer therapy. Cancer Res; 70(2); 621–31

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-09-2340

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 206

Metadata

Authors
Yu, K., Shi, C., Toral-Barza, L., Lucas, J., Shor, B., Kim, J. E., Zhang, W.-G., Mahoney, R., Gaydos, C., Tardio, L., Kim, S. K., Conant, R., Curran, K., Kaplan, J., Verheijen, J., Ayral-Kaloustian, S., Mansour, T. S., Abraham, R. T., Zask, A., & Gibbons, J. J.
Venue
Cancer Research
Published
2010-01-13
Volume
70
Issue
2
Pages
621-631
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W1976979132
Cited by
206
References
9
FWCI
10.99
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Beyond Rapalog Therapy: Preclinical Pharmacology and Antitumor Activity of WYE-125132, an ATP-Competitive and Specific Inhibitor of mTORC1 and mTORC2. https://app.cochat.ai/papers/10.1158/0008-5472.can-09-2340
The paper
Yu, K., Shi, C., Toral-Barza, L., Lucas, J., Shor, B., Kim, J. E., Zhang, W.-G., Mahoney, R., Gaydos, C., Tardio, L., Kim, S. K., Conant, R., Curran, K., Kaplan, J., Verheijen, J., Ayral-Kaloustian, S., Mansour, T. S., Abraham, R. T., Zask, A., & Gibbons, J. J. (2010). Beyond Rapalog Therapy: Preclinical Pharmacology and Antitumor Activity of WYE-125132, an ATP-Competitive and Specific Inhibitor of mTORC1 and mTORC2. Cancer Research. https://doi.org/10.1158/0008-5472.can-09-2340

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.